Can Protein Support Lung Health? What the Trials Actually Show

Protein may help some people maintain the physical reserve needed to breathe, move, and recover well. It has not earned a place beside inhalers, vaccines, pulmonary rehabilitation, or smoking cessation as a proven lung treatment.

The most encouraging direct signal comes from a 2026 randomized trial in older adults: whey protein supplementation produced statistically significant improvements in several spirometry measures, inflammatory markers, muscle strength, and functional capacity. A separate randomized trial in pulmonary rehabilitation found that individualized nutrition support helped nutritionally vulnerable patients preserve fat-free mass over three weeks. Those are useful findings. Neither trial showed fewer infections, COPD exacerbations, hospital admissions, or deaths.

The practical case for protein is therefore narrower than "whey improves lung health." It is strongest when low intake, malnutrition risk, sarcopenia, or rehabilitation already puts muscle and nutritional status at the center of the problem.

One whey trial found better lung-related markers in older adults

In a randomized controlled clinical trial, Moura-Maia et al. (2026) reported statistically significant improvements after whey protein supplementation in older adults. The outcomes included FEV1, the FEV1/FVC ratio, mid-expiratory flow (FEF25–75%), and peak expiratory flow. The trial also reported significant changes in exhaled nitric oxide (FeNO), inflammatory measures including IL-6, TNF-alpha, and IL-10, Klotho, functional capacity, expiratory muscle strength, and peripheral muscle strength.

That combination makes the study interesting. Spirometry tests airflow; FeNO and cytokines track biological processes related to airway and systemic inflammation; strength and functional capacity address the machinery that supports activity. A single intervention moved measures across all of those domains.

But the result needs careful handling. The accessible publication record reports that the outcomes were statistically significant, yet it does not provide the absolute changes, confidence intervals, or enough methodological detail to judge clinical importance, durability, or risk of bias. A statistically significant increase in FEV1 can matter greatly, barely matter at all, or reflect a result that needs replication; the size of the change decides that question. The publication record does not let readers answer it.

Nor do biomarker shifts prove a lung-specific mechanism. Lower or altered inflammatory markers may accompany better health, but they do not establish why spirometry changed, and they do not show that whey prevents respiratory disease. This is a promising surrogate-outcome result, not evidence that a shake will keep pneumonia, COPD flares, or winter viruses away.

Rehabilitation nutrition addresses a different problem

The more clinically grounded trial tested nutrition in people who already had a clear nutritional vulnerability. Coiro et al. (2025) conducted an open-label, single-center randomized controlled trial during three weeks of inpatient pulmonary rehabilitation. Participants had COPD or were recovering after pneumonia, were at risk for malnutrition on the Nutritional Risk Screening 2002 tool, and screened positive for sarcopenia risk on SARC-F.

All participants received standardized fortified care. The intervention group also received individualized nutritional therapy led by a dietitian twice weekly. Randomization was 1:1 and stratified by diagnosis, sex, age, and baseline energy intake. Compared with standardized care alone, individualized therapy improved energy and protein intake and helped preserve nutritional status and fat-free mass during rehabilitation.

This is not a direct test of whey, and it is not evidence that nutrition therapy improves lung function. It tests whether targeted nutrition can keep vulnerable patients from losing ground while they work through rehabilitation. That outcome matters because low muscle mass and poor intake can limit training tolerance and recovery. Still, the study did not establish superiority for respiratory events, readmission, six-minute walk distance, quality of life, or long-term decline.

The distinction is practical. A person entering pulmonary rehabilitation with nutritional risk may need enough energy and protein to participate and retain lean tissue. That is a different claim from telling a healthy adult to add whey for "pulmonary resilience."

The muscle evidence is stronger than the lung evidence

Protein interventions have a more consistent record for muscle-related outcomes in older adults, especially when paired with resistance exercise. A 2022 systematic review and meta-analysis by Kirwan et al. found that protein interventions augmented resistance training's effects on appendicular lean mass and handgrip strength in older adults. That supports protein as an adjunct to training, not as a substitute for it.

Whey-focused evidence points in the same direction. A 2023 systematic review and meta-analysis by Kamińska et al. concluded that whey protein supplementation could attenuate sarcopenia progression in older people. Another 2023 meta-analysis evaluated whey alongside resistance exercise in sarcopenic adults aged 60 or older and reported improved skeletal muscle mass and strength. These studies make the rehabilitation rationale plausible: preserving muscle may support physical capacity in people with respiratory disease.

They do not establish that added muscle directly improves lung outcomes. Respiratory disease has its own biology, treatments, and constraints. Better handgrip strength does not automatically mean fewer exacerbations.

The broader nutrition literature also argues against treating a supplement as a stand-alone intervention. A 2021 review and meta-analysis found that the effects of nutritional interventions combined with resistance training were heterogeneous. A 2026 review likewise places amino-acid supplementation within multimodal sarcopenia care. The pattern is sensible: adequate protein can help build or preserve tissue, but training, illness severity, baseline diet, and adherence all influence the result.

Why nutrition belongs in respiratory care anyway

Nutrition deserves attention in COPD and pulmonary rehabilitation because sarcopenia is common in COPD and is associated with poorer strength, functional capacity, and quality of life. A 2025 review of sarcopenia in COPD estimates that sarcopenia affects 20% to 40% of people with COPD, while also emphasizing exercise, targeted nutrition, and other components of care rather than any single supplement.

A 2025 narrative review of medical nutrition therapy in COPD reaches a similarly restrained conclusion: screen for nutritional risk and body-composition problems, address inadequate intake, and integrate nutrition with pulmonary rehabilitation. Narrative reviews provide clinical context, but they do not replace large randomized trials measuring outcomes patients feel and clinicians act on.

Pulmonary rehabilitation itself has evidence beyond COPD. A 2025 meta-analysis of randomized trials in long COVID found that pulmonary rehabilitation can improve relevant outcomes, with effects varying by program type and duration. It did not test protein or nutrition therapy, so it cannot be used to claim that whey improves long-COVID recovery.

What the evidence supports—and what it does not

Protein-focused nutrition is reasonable when ordinary food intake falls short, when a clinician identifies malnutrition or sarcopenia risk, or when a person is undertaking resistance training or pulmonary rehabilitation. Whey can be a convenient way to deliver protein; convenience is a legitimate advantage when appetite, fatigue, or meal preparation becomes a barrier.

The evidence does not identify the best protein dose, duration, or supplement formula for lung outcomes. It also does not show whether benefits concentrate among people with low baseline protein intake, whether whole-food approaches work as well as supplements, or how long-term tolerability differs across dairy intolerance and kidney-function contexts. Anyone with kidney disease, major dietary restrictions, unexplained weight loss, or chronic respiratory illness should individualize nutrition advice with a clinician or registered dietitian.

Verdict: Treat protein as support for nutritional status and muscle during aging or rehabilitation, not as a proven therapy for the lungs. The whey trial offers an early, statistically significant signal in lung-related surrogate measures. The stronger surrounding evidence supports muscle preservation—especially alongside exercise—and targeted nutrition in vulnerable patients.

What would change the conclusion? Larger, fully reported randomized trials in respiratory-risk populations that measure dyspnea, exercise tolerance, exacerbations, admissions, and mortality. Until then, protein can help supply the building blocks; it has not proved that it changes the respiratory finish line.